



Meldola, 14/11/2018

Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Laura Mercatali**

Address(es)

Telephone(s)

E-mail **laura.mercatali@irst.emr.it**

Nationality **Italian**

Date of birth

Gender **Female**

Il/la sottoscritta Laura Mercatali,,
consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni penali previste dall'art. 76
del D.P.R. 445/2000, dichiara che le informazioni riportate nel seguente curriculum vitae, redatto in
formato europeo, corrispondono a verità.

Occupational field **Researcher in translational oncology**

Work experiences

Dates **09/2015→**

Occupation or position held **Senior Researcher; Lab referent for Osteoncology and rare Tumors; contratto Dirigenti della ricerca,
Alta Specializzazione, Fascia A**

Main activities and responsibilities **Laboratory biologist. Main activities: paper and grant drafting; coordination of lab researchers
activities of CDO-TR together with the director of the Pathology group; Conceiving of translational
studies ; Participation to multidisciplinary meetings of CDO-TR; participation to Bioscience Lab
meetings on research, and lab management.; lab activities: cell cultures, molecular biology..
Projects topic: translational research in osteoncology and rare tumors, in particular neuro-oncology**

Name and address of employer **Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei
tumori (IRST),
40, Piero Maroncelli rd, 47014 Meldola (FC) Italy**

Type of business or sector **Translational research; Referrent for the translational research of CDO-TR team**

Dates

Occupation or position held

Name and address of employer **01/2008→08/2015**

Type of business or sector **Senior Researcher; Lab referent for Osteoncology and rare Tumors**

Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction.
Article drafting and editing. Conceiving of translational studies. Coordination of a team of researchers
Projects topic: translational research in osteoncology

	Dates	Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli rd, 47014 Meldola (FC) Italy
Occupation or position held		Translational research and support to clinical diagnostic
Main activities and responsibilities		
	Name and address of employer	1/2003-12/2007
	Type of business or sector	Junior Researcher
	Dates	Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction. Article drafting and editing. Conceiving of translational studies. Projects topic: translational research in osteoncology
Occupation or position held		Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli 47014 Meldola (FC) Italy
Main activities and responsibilities		Translational research and support to clinical diagnostic
	Name and address of employer	03/2002-12/2002
	Type of business or sector	Voluntary worker
	Dates	Laboratory biologist. Main activities: DNA extraction, RT-PCR, database implementation.
Occupation or position held		Bioscience Laboratory, Ospedale Pierantoni, Via Forlanini 34 Forlì (FC), Italy
Main activities and responsibilities		Translational research and support to clinical diagnostic
	Name and address of employer	01/2002 - 07/2002
	Type of business or sector	Researcher in experimental oncology

Education and training

	Dates	2013 jun-set
Type of qualification awarded		VSRC at Princeton University
Principal subjects/occupational skills covered		
	Dates	2010→2014
Title of qualification awarded		PHD
Principal subjects/occupational skills covered		Pharmacology, Oncology
Name and type of organisation providing education and training		Alma mater studiorum, Bologna University, Pharmacology Faculty
	Dates	2003-2005
Title of qualification awarded		MSC in toxicology (pharmaceutical curriculum) (maximum votation)
Principal subjects/occupational skills covered		Toxicology, Pharmacology, Cancerogenesis process
Name and type of organisation providing education and training		Alma mater studiorum, Bologna University, Pharmacology Faculty
Level in national or international classification		
	Dates	2002
Title of qualification awarded		Qualification to the profession of biologist; Registration in the Register "Albo dei Biologi" dal 8/11/2002 (numero d'iscrizione AA_052450)

Dates	10/1996 - 12/2001						
Title of qualification awarded	Degree in Biomolecular biology (110/100 e lode)						
Principal subjects/occupational skills covered	English language, cellular and molecular biology, Oncology, data analysis,						
Name and type of organisation providing education and training	Bologna University, Faculty of Bioscience						
Level in national or international classification	Second level Degree/ Specialistic Degree						
Other language(s)							
Self-assessment <i>European level (*)</i>							
English	B2	Independent user	B2	Independent user	B2	Independent user	B2
	(*) Common European Framework of Reference for Languages						
Social skills and competences	Able to work with a group of people on a team, especially in laboratory where is required collaboration between different professional figures						
Technical skills and competences	Good expertise on paper drafting and editing; grant drafting. Good knowledge of laboratory techniques in particular cells cultures, western blot, PCR, DNA and RNA extraction and basic knowledge of cytometry						
Computer skills and competences	Good knowledge of Office packet, in particular word and excel. Basic Knowledge of statistical analysis programs, as SPSS and GraphPad						
Driving licence	Car driving licence						
Honor and award	2012: win a travel grant of 400\$ for an abstract sent to IBCD 2012 (IBMS) 2013: Winner of Francesco Baracca Ward as a I RST researcher 2014: Winner of premio Berlucci Giovani ricercatori 2017: winner of the grant financed by progetto Giovani Ricercatori" GR-2016-02364704 entitled An in vitro and ex vivo model of biomimetic regenerative devices to treat bone metastases and soft tissue tumors: BIOBOS PROJECT						
Publications	H index: 19;62 papers						

1. Liverani C, De Vita A, Minardi S, Kang Y, Mercatali L, Amadori D, Bongiovanni A, La Manna F, Ibrahim T, Tasciotti E. A biomimetic 3D model of hypoxia-driven cancer progression. Sci Rep. 2019 Aug 22;9(1):12263. doi: 10.1038/s41598-019-48701-4.
2. Bongiovanni A, Recine F, Fausti V, Rossi B, Mercatali L, Liverani C, De Vita A, Gurrieri L, De Bonis S, Miserocchi G, Spadazzi C, Calpona S, Riva N, Cocchi C, Ibrahim T. Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: An evidence-based review. Int J Clin Pract. 2019 Aug 13:e13404. doi: 10.1111/ijcp.13404
3. Spadazzi C, Recine F, Mercatali L, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Fausti V, Ibrahim T. mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model. J Bone Oncol. 2019 Feb 27;16:100227. doi: 10.1016/j.jbo.2019.100227. eCollection 2019 Jun.

4. Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T. Ten-year experience of the multidisciplinary Osteoncology Center. *Support Care Cancer*. 2019 Sep;27(9):3395-3402. doi: 10.1007/s00520-019-4635-5.
5. Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. *Dis Markers*. 2018 Dec 2;2018:6878409. doi: 10.1155/2018/6878409. eCollection 2018.
6. Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. *Endocr Connect*. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478.
7. Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, Pieri F, Riva N, Bongiovanni A, Casadei R, Fausti V, Ibrahim T. Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line. *Cells*. 2018 Oct 25;7(11). pii: E186. doi: 10.3390/cells7110186. IF 4.829
8. Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D. Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers. *J Vis Exp*. 2018 Jun 11;(136). doi: 10.3791/57113. IF 1.184
9. De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T. Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma. *J Vis Exp*. 2018 Apr 11;(134). doi: 10.3791/56767. IF 1.184
10. De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. *Ther Adv Med Oncol*. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28. IF 6.238
11. De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T. Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. *Int J Mol Sci*. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662. IF 3.6867
12. Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(46):e8567. doi: 10.1097/MD.00000000000008567. Review. IF 2.028
13. Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T. Primary leiomyosarcoma of the bone: a case report and a review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(45):e8545. doi: 10.1097/MD.00000000000008545. Review. IF 2.028
14. Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Management and potentialities of primary cancer cultures in preclinical and translational studies. *J Transl Med*. 2017 Nov 7;15(1):229. doi: 10.1186/s12967-017-1328-z. Review. IF 4.197
15. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines. *J Vis Exp*. 2017 Sep 13;(127). doi: 10.3791/56311. IF 1.184
16. Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, Bongiovanni A, Recine F, Amadori D, Ghetti M, Ibrahim T. Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. *Int J Mol Sci*. 2017 Jul 29;18(8). pii: E1655. doi: 10.3390/ijms18081655. IF 3.687
17. Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. *Onco Targets Ther*. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017. Review. IF 2.656
18. Amadori D, Serra P, Masalu N, Pangan A, Scarpi E, Bugingo AM, Katabalo D, Ibrahim T, Bongiovanni A, Miserocchi G, Spadazzi C, Liverani C, Turri V, Tedaldi R, Mercatali L. Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. *Oncotarget*. 2017 Feb 21;8(8):13142-13156. doi: 10.18632/oncotarget.14482. IF 5.008

19. Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT. *Clin Lung Cancer*. 2017 Jul;18(4):415-420. doi: 10.1016/j.clcc.2016.11.004. Epub 2016 Nov 21
20. De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, Amadori D, Ibrahim T. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma. *Molecules*. 2016 Dec 3;21(12). Doi: 10.3390/molecules21121662 IF 2.861
21. Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, Amadori D, Puisieux A, Rigaud M, Fabbri F. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. *Oncotarget*. 2017 Jan 10;8(2):2423-2436. doi: 10.18632/oncotarget.13682. IF 5.008
22. Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T. Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. *Biol Open*. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: *Biol Open*. 2017 Feb 15;6(2):309. IF 2.095
23. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. *Int J Mol Sci*. 2016 Nov 1;17(11). Doi: 10.3390/ijms17111827 pii: E1827. IF 3.687
24. De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T. Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. *Onco Targets Ther*. 2016 Oct 11;9:6233-6246. Doi: 10.2147/OTT.S112580 eCollection 2016. Review. 2.612
25. Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, Liverani C, De Vita A, La Manna F, Oboldi D, Serra P, Foca F, Ceconetto L, Amadori D, Mercatali L. RANKL: A promising circulating marker for bone metastasis response. *Oncol Lett*. 2016 Oct;12(4):2970-2975. Doi: 10.3892/ol.2016.4977 Epub 2016 Aug 8. IF 1.390
26. Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). *Support Care Cancer*. 2017 Jan;25(1):111-117. Doi: 10.1007/s00520-016-3390-0 Epub 2016 Aug 27. IF 2.698
27. Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E. Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. *Int J Mol Sci*. 2016 Aug 22;17(8). pii: E1375. doi: 10.3390/ijms17081375. IF 3.226
28. Bongiovanni A, Riva N, Ricci M, Mercatali L, Liverani C, La Manna F, De Vita A, Cavaliere D, Pieri F, Oboldi D, Verdecchia GM, Amadori D, Ibrahim T. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report. *BMC Cancer*. 2015 Dec 22;15:998. doi: 10.1186/s12885-015-2038-7. IF 3.265
29. Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T. First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. *Onco Targets Ther*. 2015 Dec 3;8:3613-9. doi: 10.2147/OTT.S91971. eCollection 2015. IF 2.272
30. Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. *Future Oncol*. 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159. IF 2.447
31. Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review

of the literature. *Onco Targets Ther.* 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014. IF 2.311

32. Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. *Future Oncol.* 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36. IF 2.611
33. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, Kang Y. Δ Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol.* 2014 Oct;16(10):1004-15. doi: 10.1038/ncb3040. Epub 2014 Sep 21. IF 20.058
34. Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim T, Amadori D, Kang Y. The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. *J Biol Chem.* 2014 Aug 8;289(32):21888-95. doi: 10.1074/jbc.M114.582866. Epub 2014 Jun 25. IF 4.6
35. Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. *Bone.* 2014 Sep;66:214-22. doi: 10.1016/j.bone.2014.06.017. IF 3.973
36. Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review). *Oncol Lett.* 2013 Aug;6(2):306-310. Doi: 10.3892/ol.2013.1372 Epub 2013 Jun 4. IF 0.237
37. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. *Cancer Cell.* 2013 Oct 14;24(4):542-56. doi: 10.1016/j.ccr.2013.09.008. IF 24.775
38. Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. *Clin Cases Miner Bone Metab.* 2013 May;10(2):121-3. Review. IF
39. Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T. What can we learn from the ZOOM trial?--Authors' reply. *Lancet Oncol.* 2013 Sep;14(10):e388-90. doi: 10.1016/S1470-2045(13)70295-X. IF 25.117
40. Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. *Int J Mol Sci.* 2013 May 23;14(6):10683-93. doi: 10.3390/ijms140610683. IF 2.464
41. Ibrahim T, Farolfi A, Mercatali L, Ricci M, Amadori D. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. *Tumori.* 2013 Jan-Feb;99(1):1-9. doi: 10.1700/1248.13780. Review. IF 0.922
42. Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W. Multiple marker detection in peripheral blood for NSCLC diagnosis. *PLoS One.* 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401. Epub 2013 Feb 26. IF 3.730
43. Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. *Int J Oncol.* 2013 Apr;42(4):1263-70. doi: 10.3892/ijo.2013.1809. Epub 2013 Feb 6. IF 2.675
44. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. *Nat Cell Biol.* 2013 Mar;15(3):284-94. doi: 10.1038/ncb2690. Epub 2013 Feb 10. IF 20.761
45. Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. *Oncology.* 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.

46. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int.* 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48. IF 1.971
47. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukačičin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y. E1f5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nat Cell Biol.* 2012 Nov;14(11):1212-22. doi: 10.1038/ncb2607. Epub 2012 Oct 21. IF 19.49
48. Korpai M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. *Nat Med.* 2011 Aug 7;17(9):1101-8. doi: 10.1038/nm.2401. IF 22.462
49. Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. *Clin Breast Cancer.* 2011 Dec;11(6):369-75. doi: 10.1016/j.clbc.2011.05.001. Epub 2011 Jul 20. IF 2.375
50. Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. *Oncology.* 2011;80(3-4):225-31. doi: 10.1159/000327585. Epub 2011 Jul 5.
51. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Bone metastases detection by circulating biomarkers: OPG and RANKL. *Int J Oncol.* 2011 Jul;39(1):255-61. doi: 10.3892/ijo.2011.1001. Epub 2011 Apr 13.
52. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. *J Clin Pharmacol.* 2012 Mar;52(3):361-9. doi: 10.1177/0091270010396710. Epub 2011 Mar 7.
53. Casoni GL, Ulivi P, Mercatali L, Chilosi M, Tomassetti S, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. *Int J Biol Markers.* 2010 Oct-Dec;25(4):229-35.
54. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. *Cancer.* 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896. Review. (Cit 87)
55. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D. Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. *Tumori.* 2009 May-Jun;95(3):291-7.
56. Ulivi P, Mercatali L, Zoli W, Dell'amore D, Poletti V, Casoni GL, Scarpi E, Flamini E, Amadori D, Silvestrini R. Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. *Thorax.* 2008 Sep;63(9):843-4. doi: 10.1136/thx.2008.102178. No abstract available.
57. Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, Amadori D. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. *Oncologist.* 2008 Mar;13(3):330-6. doi: 10.1634/theoncologist.2007-0159.
58. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D. *Clin Cancer Res.* 2006 Dec 1;12(23):6985-8. Doi: 10.1158/1078-0432.CCR-06-1931
59. Santucci MA, Mercatali L, Brusa G, Pattacini L, Barbieri E, Perocco P. Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. *Environ Mol Mutagen.* 2003;41(5):315-21. Doi: 10.1002/em.10162
60. Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, Folli S, Gaudio M, Frassinetti GL, Amadori D, Flamini E. RT-PCR determination of maspin and mamoglobin B in peripheral blood of healthy donors and breast cancer patients. *Ann Oncol.* 2006 Mar;17(3):424-8. Epub 2005 Dec 15.

61. Santucci MA, Mercatali L, Brusa G, Pattacini L, Barbieri E, Perocco P. Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. *Environ Mol Mutagen.* 2003;41(5):315-21.
62. Barbieri L, Brigotti M, Perocco P, Carnicelli D, Ciani M, Mercatali L, Stirpe F. Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts. *FEBS Lett.* 2003 Mar 13;538(1-3):178-82.

NB: ai sensi della L. n. 196/03, si autorizza l'Ente/Società al trattamento dei dati personali qui riportati ai fini esclusivi legati alle collaborazioni professionali.